DNA repair pathways in ovarian cancer: Implications for therapy and resistance

Area of Science:

• Gynecologic Oncology
• Cancer Genomics
• DNA Repair Mechanisms

Background:

• Ovarian cancer (OC) is the deadliest gynecologic malignancy, characterized by high genomic instability and frequent resistance to standard treatments.
• Defects in DNA damage response (DDR) pathways, particularly homologous recombination deficiency, are common in OC and influence treatment outcomes.
• Genotoxic agents like platinum compounds are standard OC treatments, but resistance limits their effectiveness.

Purpose of the Study:

• To review the impact of DNA repair pathway dysregulation in OC on therapy resistance, survival, and risk.
• To discuss current and emerging DDR-targeted therapies for ovarian cancer.
• To highlight future research directions for improving clinical outcomes in OC.

Main Methods:

• Literature review of studies on DNA repair pathways in ovarian cancer.
• Analysis of the role of DNA damage response (DDR) alterations in OC.
• Examination of therapeutic strategies targeting DDR in OC.

Main Results:

• Dysregulation of DNA repair pathways significantly contributes to OC therapy resistance and impacts patient survival.
• Homologous recombination deficiency is a key feature in OC, offering therapeutic opportunities.
• Emerging DDR-targeted therapies show promise for enhancing treatment efficacy.

Conclusions:

• Understanding DDR defects is crucial for overcoming therapy resistance in ovarian cancer.
• Targeting DNA repair pathways represents a promising strategy for improving OC patient outcomes.
• Further research into DDR mechanisms and targeted therapies is essential for advancing OC treatment.